|
1
|
Mao W, Zhang L, Wang Y, Sun S, Wu J, Sun J, Zou X, Chen M, Zhang G. Cisplatin induces acute kidney injury by downregulating miR-30e-5p that targets Galnt3 to activate the AMPK signaling pathway. ENVIRONMENTAL TOXICOLOGY 2024; 39:1567-1580. [PMID: 38010663 DOI: 10.1002/tox.24054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 11/29/2023]
Abstract
Cisplatin nephrotoxicity is an etiological factor for acute kidney injury (AKI). MicroRNA (miRNA) expression is dysregulated in cisplatin-induced AKI (cAKI) although the underlying mechanisms are unclear. A cAKI model was established by intraperitoneally injecting cisplatin, and key miRNAs were screened using high-throughput miRNA sequencing. The functions of key miRNAs were determined using the cell viability, live/dead, reactive oxygen species (ROS), and 5-ethynyl-2'-deoxyuridine (EdU) proliferation assays. Additionally, the macrophage membrane was wrapped around a metal-organic framework (MOF) loaded with miRNA agomir to develop a novel composite material, macrophage/MOF/miRNA agomir nanoparticles (MMA NPs). High-throughput miRNA sequencing revealed that miR-30e-5p is a key miRNA that is downregulated in cAKI. The results of in vitro experiments demonstrated that miR-30e-5p overexpression partially suppressed the cisplatin-induced or lipopolysaccharide (LPS)-induced downregulation of cell viability, proliferation, upregulation of ROS production, and cell death. Meanwhile, the results of in vivo and in vitro experiments demonstrated that MMA NPs alleviated cAKI by exerting anti-inflammatory effects. Mechanistically, cisplatin downregulates the expression of miR-30e-5p, and the downregulated miR-30e-5p can target Galnt3 to activate the adenosine 5'-monophosphate activated protein kinase (AMPK) signaling pathway, which promotes the progression of AKI. Our study found that miR-30e-5p is a key downregulated miRNA in cAKI. The downregulated miR-30e-5p promotes AKI progression by targeting Galnt3 to activate the AMPK signaling pathway. The newly developed MMA NPs were found to have protective effects on cAKI, suggesting a potential novel strategy for preventing cAKI.
Collapse
Affiliation(s)
- Weipu Mao
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
- Department of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
| | - Lei Zhang
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
| | - Yiduo Wang
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
| | - Si Sun
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
| | - Jianping Wu
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
- Department of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
| | - Jie Sun
- Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xiangyu Zou
- Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- School of Basic Medical Sciences, Weifang Medical University, Weifang, China
| | - Ming Chen
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
- Department of Urology, Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
| | - Guangyuan Zhang
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China
| |
Collapse
|
|
2
|
Reynisdottir I, Arason A, Freysteinsdottir ES, Kristjansdottir SB, Hilmarsdottir B, Traustadottir GA, Johannsson OT, Agnarsson BA, Barkardottir RB. High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer. Genes (Basel) 2023; 14:1559. [PMID: 37628611 PMCID: PMC10454310 DOI: 10.3390/genes14081559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/21/2023] [Accepted: 07/26/2023] [Indexed: 08/27/2023] Open
Abstract
The disruption of endoplasmic reticulum (ER) homeostasis occurs in many human diseases. Atlastins (ATLs) maintain the branched network of the ER. The dysregulation of ATL2, located at ER network junctions, has been associated with cancer. ATL2 is necessary for lipid droplet formation in murine breast tissue. Thus, we analyzed whether ATL2 has a role in human breast cancer (BC) pathology. The expression of ATL2 variant ATL2-2 was analyzed in breast tumors from the BC cohorts of the TCGA, METABRIC, and two independent Icelandic cohorts, Cohort 1 and 2; its association with clinical, pathological, survival, and cellular pathways was explored. ATL2-2 mRNA and protein expression were higher in breast tumors than in normal tissue. ATL2-2 mRNA associated with tumor characteristics that indicate a worse prognosis. In METABRIC, high ATL2-2 mRNA levels were associated with shorter BC-specific survival (BCSS) in patients with estrogen-receptor-positive luminal breast tumors, which remained significant after correction for grade and tumor size (HR 1.334, CI 1.063-1.673). Tumors with high ATL2 mRNA showed an upregulation of hallmark pathways MYC targets v1, E2F targets, and G2M checkpoint genes. Taken together, the results suggest that high levels of ATL2-2 may support BC progression through key cancer driver pathways.
Collapse
Affiliation(s)
- Inga Reynisdottir
- Cell Biology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; (A.A.); (B.H.); (G.A.T.); (R.B.B.)
| | - Adalgeir Arason
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; (A.A.); (B.H.); (G.A.T.); (R.B.B.)
- Molecular Pathology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| | - Edda S. Freysteinsdottir
- Molecular Pathology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| | - Sigrun B. Kristjansdottir
- Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland; (S.B.K.); (B.A.A.)
| | - Bylgja Hilmarsdottir
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; (A.A.); (B.H.); (G.A.T.); (R.B.B.)
- Molecular Pathology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| | - Gunnhildur A. Traustadottir
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; (A.A.); (B.H.); (G.A.T.); (R.B.B.)
- Molecular Pathology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| | - Oskar T. Johannsson
- Department of Oncology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| | - Bjarni A. Agnarsson
- Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland; (S.B.K.); (B.A.A.)
- Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
| | - Rosa B. Barkardottir
- BMC (Biomedical Center), Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland; (A.A.); (B.H.); (G.A.T.); (R.B.B.)
- Molecular Pathology Unit, Department of Pathology, Landspitali—The National University Hospital of Iceland, 101 Reykjavik, Iceland;
| |
Collapse
|